Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Factors associated with the risk of poor outcome (non-healing ulcers)

From: Poor prognostic factors in patients with newly diagnosed intestinal Adamantiades-Behçet’s disease in the Shanghai Adamantiades-Behçet’s disease database: a prospective cohort study

 Univariate analysisMultivariate analysis
OR (95% CI)POR (95% CI)P
Male sex1.01 (0.61–1.70)0.959
Age at the diagnosis of BS > 35 years1.06 (0.63–1.77)0.833
Onset of BS < 7 years1.39 (0.85–2.27)0.190
Intestinal symptoms1.08 (0.64–1.82)0.766
Endoscopic characteristics  
Location (ileocecal and colorectum)2.58 (1.63–4.07)0.0007.10 (1.81–27.86)0.005
Number, ≥ 31.21 (0.72–2.04)0.463
Size, > 1 cm1.68 (1.02–2.76)0.0493.15 (0.91–10.84)0.070
Lab parameters
WBC > 6.4, × 109/L1.56 (0.92–2.66)0.093
Hb < 123, g/L1.81 (1.05–3.11)0.026
ESR > 24, mm/h2.85 (1.54–5.28)0.0005.97 (1.73–20.53)0.005
CRP > 44, mg/L1.94 (1.19–3.17)0.014
Positive FOBT+1.16 (0.64–2.09)0.629
Positive T-SPOT0.56 (0.22–1.39)0.1640.25 (0.05–1.35)0.107
HBV-DNA0.95 (0.30–3.05)1.000
Treatment
Biologics0.30 (0.17–0.54)0.000
IFX therapy#0.24 (0.12–0.50)0.0000.18 (0.04–0.85)0.031
Poor compliance3.95 (2.35–6.62)0.0008.56 (1.91–38.26)0.005
  1. +FOBT: fecal occult blood test
  2. #IFX therapy was administrated at 0,2, and 6 weeks (intravenous), and then maintained with the same dosage of IFX every 8 weeks